WCG Wealth Advisors LLC lifted its holdings in shares of Pfizer Inc. (NYSE:PFE – Free Report) by 15.3% in the 2nd quarter, HoldingsChannel.com reports. The fund owned 32,347 shares of the biopharmaceutical company’s stock after purchasing an additional 4,295 shares during the quarter. WCG Wealth Advisors LLC’s holdings in Pfizer were worth $905,000 as of its most recent filing with the Securities and Exchange Commission.
Several other hedge funds and other institutional investors also recently made changes to their positions in the business. FAS Wealth Partners Inc. boosted its stake in Pfizer by 1.3% in the 2nd quarter. FAS Wealth Partners Inc. now owns 26,306 shares of the biopharmaceutical company’s stock valued at $736,000 after purchasing an additional 342 shares during the period. Sachetta LLC boosted its stake in Pfizer by 7.3% in the 2nd quarter. Sachetta LLC now owns 5,010 shares of the biopharmaceutical company’s stock valued at $140,000 after purchasing an additional 342 shares during the period. Ironvine Capital Partners LLC boosted its stake in Pfizer by 2.1% in the 1st quarter. Ironvine Capital Partners LLC now owns 16,953 shares of the biopharmaceutical company’s stock valued at $470,000 after purchasing an additional 353 shares during the period. Secure Asset Management LLC boosted its stake in Pfizer by 0.6% in the 2nd quarter. Secure Asset Management LLC now owns 58,328 shares of the biopharmaceutical company’s stock valued at $1,632,000 after purchasing an additional 353 shares during the period. Finally, Patrick M Sweeney & Associates Inc. boosted its stake in Pfizer by 0.8% in the 2nd quarter. Patrick M Sweeney & Associates Inc. now owns 42,162 shares of the biopharmaceutical company’s stock valued at $1,180,000 after purchasing an additional 355 shares during the period. 68.36% of the stock is currently owned by institutional investors.
Pfizer Price Performance
Pfizer stock opened at $29.67 on Friday. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.60 and a current ratio of 0.86. Pfizer Inc. has a 52 week low of $25.20 and a 52 week high of $34.11. The stock has a market capitalization of $168.13 billion, a P/E ratio of -494.42, a price-to-earnings-growth ratio of 1.02 and a beta of 0.68. The stock has a fifty day moving average of $29.35 and a 200-day moving average of $28.20.
Pfizer Dividend Announcement
The company also recently announced a quarterly dividend, which was paid on Tuesday, September 3rd. Shareholders of record on Friday, July 26th were issued a $0.42 dividend. The ex-dividend date was Friday, July 26th. This represents a $1.68 dividend on an annualized basis and a yield of 5.66%. Pfizer’s payout ratio is presently -2,799.53%.
Wall Street Analyst Weigh In
Several research firms recently issued reports on PFE. Daiwa America upgraded Pfizer from a “moderate buy” rating to a “strong-buy” rating in a research note on Wednesday, August 7th. StockNews.com upgraded Pfizer from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st. UBS Group upped their target price on Pfizer from $30.00 to $31.00 and gave the company a “neutral” rating in a research report on Wednesday, July 31st. Cantor Fitzgerald reiterated an “overweight” rating and set a $45.00 target price on shares of Pfizer in a research report on Monday. Finally, Wells Fargo & Company upped their target price on Pfizer from $28.00 to $30.00 and gave the company an “equal weight” rating in a research report on Wednesday, July 31st. Eight investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $34.54.
Check Out Our Latest Stock Report on PFE
Pfizer Company Profile
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
Featured Articles
- Five stocks we like better than Pfizer
- 10 Best Airline Stocks to Buy
- Edgewise Therapeutics Soars 50%: Key Reasons Behind the Surge
- ETF Screener: Uses and Step-by-Step Guide
- How the Fed’s Rate Cut Could Supercharge These 3 ETFs
- The 3 Best Fintech Stocks to Buy Now
- Microsoft Stock: 3 Reasons It’s Ready to Crush Q4
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE – Free Report).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.